期刊文献+

碳酸镧所致不良反应文献分析 被引量:5

Literature Analysis of Adverse Drug Reactions Induced by Lanthanum Carbonate
下载PDF
导出
摘要 目的:分析碳酸镧所致药品不良反应(ADR)的发生情况,为临床安全用药提供参考。方法:收集国内外公开报道的碳酸镧ADR的文献资料,按患者年龄、性别、原患疾病,ADR发生时间、累及器官及临床表现、转归等进行整理分析。结果:共收集到碳酸镧ADR16例,男9例(56%),女7例(44%),年龄61~70岁患者10例(62. 5%),发生时间尤其应注意用药后4年以上(33. 33%)。累及器官主要有胃肠系统,临床表现有恶心、呕吐、腹痛、麻痹性肠梗阻、腹膜炎等。1例(6. 25%)患者死亡。结论:碳酸镧所致ADR需引起临床高度重视,注意患者用药教育及随访,避免严重不良反应的发生。 Objective: To study the effects of lanthanum carbonate( LC) adverse drug reactions( ADR) occurred,and provide reference for clinical rational and safe medication. Methods:LC ADRs domestically and internationally reported were collected and analysed in respects of age,gender,the original illness,ADR occurrence time,clininal manifestations and the results. Results:After retrieval,there were 16 cases of LC ADRs,including 9 men(56%) and 7 women(44%). Patients over the age of 61-70 years showed the higher incidence(n = 10,62. 5%). The occurrence time should be with particular attention within 4 years after administration(33. 33%). Main clinical manifestations were gastrointestinal system. The main clinical manifestations of LC drug reactions were nausea,emesis,stomachache,paralytic ileus and peritonitis. 1 patient(6. 25%) died. Conclusion:LC-induced ADR should be emphasized,and pay attentions to patient medication education to avoid serious adverse reactions.
作者 李璐璐 张耕 Li Lulu;Zhang Geng(Department of Pharmacy,Wuhan No.1 Hospital,Wuhan 430022,China)
出处 《药物流行病学杂志》 CAS 2018年第11期769-773,共5页 Chinese Journal of Pharmacoepidemiology
关键词 碳酸镧 药品不良反应 文献计量学 Lanthanum carbonate Adverse drug reactions Bibliometrics
  • 相关文献

参考文献4

二级参考文献57

  • 1US Renal Data System:USRDS 2008 Annual Data Report.Chapter 11:Costs of End-Stage Renal Disease.(Accessed April,16,2009,at http://www.usrds.org/2008/pdf N2_11_2008.pdf.). 被引量:1
  • 2Guerin AP,Blacher J,Pannier B,et al.Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.Circulation,2001,103 (7):987-992. 被引量:1
  • 3Hruska KA,Mathew S,Lund R,et al.Hyperphosphatemia of chronic kidney disease.Kidney Int,2008,74 (2):148-157. 被引量:1
  • 4Cozzolino M,Brancaccio D,Gallieni M,et al.Pathogenesis of parathyroid hyper-plasia in renal failure.J Nephrol,2005,18(1):5-8. 被引量:1
  • 5Silver J,Levi R.Cellular and molecular mechanisms of secondary hyperparathyroidism.Clin Nephrol,2005,63 (2):119-126. 被引量:1
  • 6Tentori F,Blayney M J,Albert JM,et al.Mortality risk for dialysis patients with different levels of serum calcium,phosphorus,and PTH:The Dialysis Outcomes and Practice Patterns Study (DOPPS).Am J Kidney Dis,2008,52(3):519-530. 被引量:1
  • 7Block GA,Klassen PS,Lazarus JM,et al.Mineral metabolism,mortality,and morbidity in maintenance hemodialysis.J Am Soc Nephro1,2004,15 (8):2208-2218. 被引量:1
  • 8Isakova T,Wahl P,Vargas GS,et al.Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int,2011,79(12):1370-1378. 被引量:1
  • 9Spasovski G,Massy Z,Vanholder R.Phosphate metabolism in chronic kidney disease:from pathophysiology to clinical management.Semin Dial,2009,22 (4):357-362. 被引量:1
  • 10Mathew S,Tustison KS,Sugatani T,et al.The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD.J Am Soc Nephrol,2008,19(6):1092-1105. 被引量:1

共引文献753

同被引文献21

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部